Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Updates and Pharmacological Associations
DOI:
https://doi.org/10.33448/rsd-v13i5.45911Keywords:
Antibiotics; Anticonvulsants; Stevens-Johnson syndrome; Adverse effects.Abstract
Introduction: The use of medications can lead to adverse reactions, including cutaneous manifestations of varying degrees. When these manifestations are severe, a spectrum of conditions including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) occurs, characterized by an exacerbated hypersensitivity reaction with subsequent apoptosis of skin keratinocytes. The aim of this study is to elucidate the association with drugs and the clinical aspects and management of these conditions. Methodology: This is an integrative review on the pharmacological associations with SJS/TEN. Data from the Virtual Health Library (BVS), Scientific Electronic Library of Medicine (SciELO), and National Library of Medicine (PubMed) were used, by crossing the descriptors "Stevens-Johnson Syndrome", "antibiotics", "anticonvulsants" and "adverse effects" to answer the question formulated through the PICO strategy. Results and Discussion: Among the drugs associated with the development of SJS/TEN, antibiotics, anti-inflammatory drugs, antiretrovirals, and anticonvulsants stand out, especially sulfonamides and penicillins from the antimicrobial group and aromatic antiepileptics. It is still unclear whether the manifestations differ depending on the causative drug. Diagnosis is usually clinical, aided by the patient's history. Tools can assist in defining management and estimating prognosis. Treatment consists of supportive care and possible pharmacological options, such as the use of cyclosporines. Conclusion: Since this is a rare and potentially fatal condition, more studies are needed to define more effective protocols for management and treatment of patients with SJS/TEN.
References
Acar, A., Yoldas, A. H., Turk, B. G., Karaarslan, I., Sagduyu, I. E., Ceylan, C., Unal, I., & Ozturk, G. (2022). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: 11-year Demographic Clinical and Prognostic Characteristics. Indian journal of dermatology, 67(1), 12–18. https://doi.org/10.4103/ijd.IJD_671_21
Arora, R., Pande, R. K., Panwar, S., & Gupta, V. (2021). Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 25(5), 575–579. https://doi.org/10.5005/jp-journals-10071-23826
Ayele, B. A., Ali, K., & Mulatu, E. (2021). Toxic epidermal necrosis associated with phenobarbitone: a case report and brief review of the literatures. Allergy, Asthma, and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology, 17(1), 88. https://doi.org/10.1186/s13223-021-00589-4
Coias, J., Abbas, L. F., & Cardones, A. R. (2019). Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update. 8(4), 219–233. https://doi.org/10.1007/s13671-019-00275-0
Frantz, R., Huang, S., Are, A., & Motaparthi, K. (2021). Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina, 57(9), 895. https://doi.org/10.3390/medicina57090895
Frey, N., Bircher, A., Bodmer, M., Jick, S. S., Meier, C. R., & Spoendlin, J. (2018). Antibiotic Drug Use and the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Population-Based Case-Control Study. The Journal of investigative dermatology, 138(5), 1207–1209. https://doi.org/10.1016/j.jid.2017.12.015
Hasegawa, A., & Abe, R. (2020). Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Research, 9, 612. https://doi.org/10.12688/f1000research.24748.1
Kanagarajan, A., Murthy, A. B., Moni, P. K., & Palanivel, N. (2023). Clinicoetiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Spectrum and the Correlation of SCORTEN with Prognosis. Indian journal of dermatology, 68(1), 25–33. https://doi.org/10.4103/ijd.ijd_783_22
Middendorf, M. M., Busaileh, A. Z., Babakhani, A., & Marik, P. E. (2019). Stevens-Johnson syndrome/toxic epidermal necrolysis: treatment with low-dose corticosteroids, vitamin C and thiamine. BMJ Case Reports, 12(11), e230538. https://doi.org/10.1136/bcr-2019-230538
Noe, M. H., & Micheletti, R. G. (2020). Diagnosis and Management of Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clinics in Dermatology. https://doi.org/10.1016/j.clindermatol.2020.06.016
Petukhova, T. A., Maverakis, E., Ho, B., & Sharon, V. R. (2016). Urogynecologic complications in Stevens-Johnson syndrome and toxic epidermal necrolysis: Presentation of a case and recommendations for management. JAAD Case Reports, 2(3), 202–205. https://doi.org/10.1016/j.jdcr.2016.03.006
Puri, P., Aslam, Z. M., Komal, F., Prachi, F., Sardana, P., & Chitkara, A. (2023). Phenytoin-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Overlap in Focus: A Case Report. Cureus, 15(9), e46075. https://doi.org/10.7759/cureus.46075
Shanbhag, S. S., Chodosh, J., Fathy, C., Goverman, J., Mitchell, C., & Saeed, H. N. (2020). Multidisciplinary care in Stevens-Johnson syndrome. Therapeutic Advances in Chronic Disease, 11, 204062231989446. https://doi.org/10.1177/2040622319894469
Sotozono, C., Ueta, M., & Kinoshita, S. (2021). Japan: Diagnosis and Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.657327
Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8(1), 102–106. https://doi.org/10.1590/s1679-45082010rw1134.
Tóth, G., Lukács, A., Schirra, F., Gábor László Sándor, Killik, P., Otto Alexander Maneschg, Zoltán Zsolt Nagy, & Nóra Szentmáry. (2023). Ophthalmic Aspects of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review. Ophthalmology and Therapy, 12(4), 1795–1811. https://doi.org/10.1007/s40123-023-00725-w
Wang, L., Varghese, S., Bassir, F., Lo, Y. C., Ortega, C. A., Shah, S., Blumenthal, K. G., Phillips, E. J., & Zhou, L. (2022). Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Frontiers in medicine, 9, 949520. https://doi.org/10.3389/fmed.2022.949520
Watson, P., Lamiaux, M., Lebas, D., & Modiano, P. (2023). Stevens-Johnson syndrome induced by lacosamide: A rare adverse reaction. Annales de dermatologie et de venereologie, 150(3), 223–224. https://doi.org/10.1016/j.annder.2022.12.001
Wattanachai, P., Amornpinyo, W., Konyoung, P., Purimart, D., Khunarkornsiri, U., Pattanacheewapull, O., Tassaneeyakul, W., & Nakkam, N. (2023). Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions. Frontiers in pharmacology, 14, 1248386. https://doi.org/10.3389/fphar.2023.1248386
Yan, Q., Liu, X., Lei, H., Liu, R., & Hu, Y. (2023). Analysis of clinical features of oxcarbazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1232969
Yoo, H. W., Kim, H. Y., Shin, K., & Kim, S. H. (2022). Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study. Asia Pacific allergy, 12(2), e17. https://doi.org/10.5415/apallergy.2022.12.e17
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ana Paula de Araújo Raimundo; Igor Oliveira Ribeiro; Julia Cambraia de Souza Brissac; Júlia Herondina Madeira Siqueira Viana; Maria Eduarda Maia Fernandes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
